PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the board of directors elected veteran biotechnology executive William Waddill as an independent director of the company, with a term beginning effective January 1, 2018 .
PASADENA, Calif.--(BUSINESS WIRE)--
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the
board of directors elected veteran biotechnology executive William
Waddill as an independent director of the company, with a term beginning
effective January 1, 2018. It is anticipated that Mr. Waddill will serve
on the Audit, Compensation, and Nomination Committees.
Douglass Given, M.D., Ph.D., Chairman of the Board of Arrowhead said,
"Will is an accomplished biotechnology executive and board member and we
look forward to working with him during this exciting time for Arrowhead
as the company advances its pipeline of RNAi-therapeutics."
William Waddill began his career 30 years ago in commercial banking and
public accounting and has been in the biotechnology industry for over 25
years. Currently, he is on the board of Protagonist Therapeutics and
most recently was Senior Vice President and CFO of Calithera Bioscience.
Prior to Calithera, Mr. Waddill was Senior Vice President and CFO at
OncoMed Pharmaceuticals from 2007 to 2014. Mr. Waddill served as the
Senior Vice President and CFO of Ilypsa, Inc., a biotechnology company
that was acquired in 2007 by Amgen, Inc. Before joining Ilypsa, he
served as the founder and principal at Square One Finance, a financial
consulting business, and Mr. Waddill served as Senior Director of
Finance and Administration at Exelixis, Inc., a biotechnology company.
Mr. Waddill received a BS in accounting from the University of Illinois,
Chicago, and certification as a public accountant (inactive) after
working at PriceWaterhouseCoopers and Deloitte in Boston.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable
diseases by silencing the genes that cause them. Using a broad portfolio
of RNA chemistries and efficient modes of delivery, Arrowhead therapies
trigger the RNA interference mechanism to induce rapid, deep, and
durable knockdown of target genes. RNA interference, or RNAi, is a
mechanism present in living cells that inhibits the expression of a
specific gene, thereby affecting the production of a specific protein.
Arrowhead's RNAi-based therapeutics leverage this natural pathway of
For more information, please visit www.arrowheadpharma.com,
or follow us on Twitter @ArrowheadPharma.
To be added to the Company's email list and receive news directly,
please visit http://ir.arrowheadpharma.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation Reform
This news release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our actual
results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and
uncertainties, including the safety and efficacy of our product
candidates, the duration and impact of regulatory delays in our clinical
programs, our ability to finance our operations, the future success of
our scientific studies, our ability to successfully develop drug
candidates, the timing for starting and completing clinical trials,
rapid technological change in our markets, and the enforcement of our
intellectual property rights. Our most recent Annual Report on Form 10-K
and subsequent Quarterly Reports on Form 10-Q discuss some of the
important risk factors that may affect our business, results of
operations and financial condition. We assume no obligation to update or
revise forward-looking statements to reflect new events or circumstances.
Source: Arrowhead Pharmaceuticals, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171227005464/en/
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
LifeSci Advisors, LLC
Source: Arrowhead Pharmaceuticals, Inc.
News Provided by Acquire Media